Newronika, a Milan, Italy-based deep brain stimulation company, raised €13.6M in Series B funding.
The round was led by Fondazione ENEA Tech Biomedical, with additional participation from existing investors Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F.
The company intends to use the funds to expand the clinical validation and commercialization of its proprietary adaptive DBS system. The funds will also facilitate the advancement of product pipelines, recruiting talent, and establishing strategic collaborations that further strengthen the company’s position at the intersection of medical device engineering and neuroscience.
Led by CEO Dr. Lorenzo Rossi, Newronika empowers deep brain stimulation (DBS) through its adaptive platform that uses real-time patient data to optimize therapy. It is designed to deliver precision therapy aimed to improve symptom relief and reduce side effects for Parkinson’s disease patients.
FinSMEs
13/02/2025